TY - JOUR
T1 - Effect of t (11;14) Abnormality on Outcomes of Patients With Newly Diagnosed Multiple Myeloma in the Connect MM Registry
AU - CONNECT MM Registry Investigators
AU - Gasparetto, Cristina
AU - Jagannath, Sundar
AU - Rifkin, Robert M.
AU - Durie, Brian G.M.
AU - Narang, Mohit
AU - Terebelo, Howard R.
AU - Toomey, Kathleen
AU - Hardin, James W.
AU - Wagner, Lynne
AU - Ailawadhi, Sikander
AU - Omel, James L.
AU - Srinivasan, Shankar
AU - Dhalla, Mazaher
AU - Catamero, Donna
AU - Kitali, Amani
AU - Agarwal, Amit
AU - Abonour, Rafat
N1 - Funding Information:
Lihua Yue and Liang Liu provided statistical support. Jane Lu and Jay Cao provided programming support. This study was funded by Celgene, a Bristol-Myers Squibb Company, which had a role in the study design, collection, analysis and interpretation of data, provided medical writing support, and was involved in the decision to submit the article for publication. Writing and editorial assistance were provided by Maryann Obiorah, PhD, of Bio Connections LLC, funded by Bristol Myers Squibb. All authors contributed to the acquisition, analysis, or interpretation of data for this article and drafts of the article; revised the manuscript critically for important intellectual content; approved the final version to be published; and agreed to be accountable for all aspects of the article. This work was supported by Celgene, a Bristol-Myers Squibb Company.
Publisher Copyright:
© 2021
PY - 2022/3
Y1 - 2022/3
N2 - Background: The t (11;14) (q13;32) translocation [t (11;14)] is present in ∼20% of patients with newly diagnosed multiple myeloma (NDMM), but studies examining its prognostic ability have yielded divergent results, and data are lacking on outcomes from first-line therapy. Patients and Methods: Data from the Connect MM Registry, a large US, multicenter, prospective observational cohort study of patients with NDMM were used to examine the effect of t (11;14) status on first-line therapy outcomes in the Overall population (n = 1574) and race groups (African American [AA] vs. non-African American [NAA]). Results: Baseline characteristics were generally similar between patients with (n = 378) and without (n = 1196) t (11;14). Prevalence of t (11;14) was similar by race (AA, 27%; NAA, 24%). In the overall population, regardless of first-line therapy, t (11;14) status did not affect progression-free survival (hazard ratio, 1.02; P = 0.7675) or overall survival (hazard ratio, 0.99; P = .9417). AA patients with t (11;14) had higher likelihood of death (Nominal Cox regression P = .0298) vs. patients without t (11;14). Conclusions: Acknowledging observational study and inferential limitations, this exploratory analysis of a predominantly community-based population suggests that t (11;14) is a neutral prognostic factor in the general MM population but may be a negative factor for overall survival in AA patients.
AB - Background: The t (11;14) (q13;32) translocation [t (11;14)] is present in ∼20% of patients with newly diagnosed multiple myeloma (NDMM), but studies examining its prognostic ability have yielded divergent results, and data are lacking on outcomes from first-line therapy. Patients and Methods: Data from the Connect MM Registry, a large US, multicenter, prospective observational cohort study of patients with NDMM were used to examine the effect of t (11;14) status on first-line therapy outcomes in the Overall population (n = 1574) and race groups (African American [AA] vs. non-African American [NAA]). Results: Baseline characteristics were generally similar between patients with (n = 378) and without (n = 1196) t (11;14). Prevalence of t (11;14) was similar by race (AA, 27%; NAA, 24%). In the overall population, regardless of first-line therapy, t (11;14) status did not affect progression-free survival (hazard ratio, 1.02; P = 0.7675) or overall survival (hazard ratio, 0.99; P = .9417). AA patients with t (11;14) had higher likelihood of death (Nominal Cox regression P = .0298) vs. patients without t (11;14). Conclusions: Acknowledging observational study and inferential limitations, this exploratory analysis of a predominantly community-based population suggests that t (11;14) is a neutral prognostic factor in the general MM population but may be a negative factor for overall survival in AA patients.
KW - African American
KW - Community
KW - Real-world
KW - Survival
KW - Translocation
UR - http://www.scopus.com/inward/record.url?scp=85115927490&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85115927490&partnerID=8YFLogxK
U2 - 10.1016/j.clml.2021.08.007
DO - 10.1016/j.clml.2021.08.007
M3 - Article
C2 - 34588149
AN - SCOPUS:85115927490
SN - 2152-2650
VL - 22
SP - 149
EP - 157
JO - Clinical Lymphoma, Myeloma and Leukemia
JF - Clinical Lymphoma, Myeloma and Leukemia
IS - 3
ER -